Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 16, 2026

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

Breast radiotherapy: less is more?

C E Coles1, A M Brunt, D Wheatley

  • 1Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. charlotte.coles@addenbrookes.nhs.uk

Clinical Oncology (Royal College of Radiologists (Great Britain))
|November 28, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Testing a 5-fraction Simultaneous Integrated Boost in Radiotherapy for Breast Cancer: The UK FAST-Forward Boost Trial Opens to Recruitment.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

What guides regional nodal irradiation in node positive breast cancer following upfront sentinel lymph node biopsy?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.

ESMO open·2025
Same author

Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Neoadjuvant Radiotherapy and Endocrine Therapy for Oestrogen Receptor Positive Breast Cancers: The Neo-RT Feasibility Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

The Assisi think tank focus review on postoperative radiation for lobular breast cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same journal

Research Trends in Physical Activity and Breast Cancer: A 25-Year Bibliometric Analysis (2000-2025).

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Concordance Between Planned and Delivered treatment for Head and Neck Cancer Patients Treated With Curative Intent: A Real-World Comparison of Under 70-year-olds With 70-year-olds and Over.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

A Novel Technique for Pain Management to Deliver a Course of Palliative Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Broad-Spectrum Antibiotics are Associated with worse Survival After Radical Treatment for Glioblastoma Multiforme: A Multicentre Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Exploring the Need for Plan Adaptation in Robustly Optimised Head and Neck Intensity Modulated Proton Therapy: A Dosimetric Perspective From Initial Institutional Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Lifting the Lid on Best Practice in a Case of Oligometastatic Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles

A 3-week whole breast radiotherapy schedule is common and shorter regimens, including single-dose partial breast treatment, are being explored. Rigorous trials are essential to confirm the safety and efficacy of hypofractionation in breast cancer care.

Area of Science:

  • Oncology
  • Radiotherapy
  • Breast Cancer Treatment

Background:

  • A 3-week whole breast radiotherapy schedule is standard in the UK and gaining international acceptance.
  • Accelerated partial breast radiotherapy regimens are increasingly common.
  • Hypofractionation, including shorter treatment schedules, is a growing area in breast cancer management.

Purpose of the Study:

  • To review the rationale behind hypofractionation for breast cancer.
  • To discuss historical radiotherapy trials.
  • To outline the design of ongoing studies investigating hypofractionated radiotherapy.

Main Methods:

  • Literature review of past and current radiotherapy trials.
  • Analysis of the rationale for hypofractionation.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Experiment Videos

Last Updated: May 16, 2026

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

  • Overview of study designs for hypofractionated breast cancer treatment.

    • Main Results:

    • The 3-week schedule is likely not the minimum for whole breast hypofractionation.
    • Partial breast irradiation may potentially be treated with a single dose.
    • Further research is needed to validate these findings.

    Conclusions:

    • Hypofractionated radiotherapy, including shorter whole breast and partial breast schedules, shows promise.
    • Well-designed clinical trials are crucial to ensure the quality and safety of these accelerated radiotherapy regimens.
    • Continued investigation is necessary to establish the optimal hypofractionation strategies for breast cancer.